Indian markets stall amid bank sell-off; analysts urge stock picking
Indian equities slid on weak private bank earnings and surging crude, forcing traders to abandon broad index plays for targeted stock positions.
Indian equity benchmarks closed lower on July 20, dragged down by a sharp sell-off in private banking stocks following disappointing June-quarter earnings. The Sensex fell 0.57% to 77,708 and the Nifty dropped 0.39% to 24,238. Heavyweights including Axis Bank, HDFC Bank, and Kotak Mahindra Bank led the declines.
The weakness was compounded by external pressures. Crude oil prices surged past $90 a barrel amid rising geopolitical tensions in West Asia, dampening broader investor sentiment and briefly dragging the Nifty below 24,200. However, late-session buying helped the benchmarks recover a significant portion of their intraday losses.
The divergent performance highlights a fractured market. While blue-chip private banks suffered, broader indices outperformed, with midcaps gaining 0.6% and smallcaps turning slightly positive. Sectoral rotation was evident as PSU banks climbed 2.8% and pharma added 1.4%, masking the underlying weakness in the primary benchmarks.
Technically, the market remains trapped in a confused, rangebound state. The formation of lower lows has pushed participants to the sidelines, even as persistent support at lower levels prevents a clean breakdown. Analysts warn that resistance at 24,100 and 23,750 will cap any recovery until there is clarity on global geopolitical risks.
Selective positioning replaces broad bets
In this environment of suppressed momentum and sudden higher-level sell-offs, broad market exposure carries elevated risk. Raja Venkatraman of NeoTrader noted that a "confused" trend is forcing a highly selective approach, recommending investors use any pullbacks to build targeted positions.
His recommendations focus on specific technical breakouts rather than macro-driven bets. Ambuja Cements, trading at 437.80, is a buy above 441 with a target of 479, buoyed by Bernstein upgrading the stock to "Outperform" to close an unsustainable valuation gap with peers. Anthem Biosciences, a Bengaluru-based CRDMO, is breaking out of a three-month consolidation phase, offering a buy above 792 with a target of 870.
Five-Star Business Finance, an NBFC lending to micro-entrepreneurs, is also exhibiting steady buying interest since March. Venkatraman recommends a long position above 573, targeting 625. For investors navigating the current Indian market, the overriding strategy is to reduce overall participation and wait for a decisive move below the 24,000 level before committing fresh capital to the major indices.
